Your browser doesn't support javascript.
loading
Pharmacologic modulation of intracellular Na+ concentration with ranolazine impacts inflammatory response in humans and mice.
Lenz, Max; Salzmann, Manuel; Ciotu, Cosmin I; Kaun, Christoph; Krychtiuk, Konstantin A; Rehberger Likozar, Andreja; Sebestjen, Miran; Goederle, Laura; Rauscher, Sabine; Krivaja, Zoriza; Binder, Christoph J; Huber, Kurt; Hengstenberg, Christian; Podesser, Bruno K; Fischer, Michael J M; Wojta, Johann; Hohensinner, Philipp J; Speidl, Walter S.
Affiliation
  • Lenz M; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Salzmann M; Ludwig Boltzmann Institute for Cardiovascular Research, A-1090 Vienna, Austria.
  • Ciotu CI; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Kaun C; Ludwig Boltzmann Institute for Cardiovascular Research, A-1090 Vienna, Austria.
  • Krychtiuk KA; Center of Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.
  • Rehberger Likozar A; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Sebestjen M; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Goederle L; Department of Vascular Disease, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
  • Rauscher S; Department of Vascular Disease, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
  • Krivaja Z; Department of Cardiology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
  • Binder CJ; Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
  • Huber K; Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
  • Hengstenberg C; Core Facility Imaging, Medical University of Vienna, 1090 Vienna, Austria.
  • Podesser BK; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Fischer MJM; Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
  • Wojta J; 3rd Medical Department, Cardiology and Intensive Care Medicine, Clinic Ottakring (Wilhelminenhospital), and Sigmund Freud University, Medical Faculty, Vienna, 1020 Austria.
  • Hohensinner PJ; Department of Internal Medicine II - Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
  • Speidl WS; Ludwig Boltzmann Institute for Cardiovascular Research, A-1090 Vienna, Austria.
Proc Natl Acad Sci U S A ; 119(29): e2207020119, 2022 07 19.
Article in En | MEDLINE | ID: mdl-35858345
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sodium / Coronary Artery Disease / C-Reactive Protein / Cardiovascular Agents / Sodium Channel Blockers / Acute Coronary Syndrome / Ranolazine Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Document type: Article Affiliation country: Austria Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sodium / Coronary Artery Disease / C-Reactive Protein / Cardiovascular Agents / Sodium Channel Blockers / Acute Coronary Syndrome / Ranolazine Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Document type: Article Affiliation country: Austria Country of publication: Estados Unidos